AAAnna Ashurov

Anna Ashurov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anna Ashurov has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Artem Ashurov

    Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne, 50931, Germany

    2 shared publications
  • Danylo Shestopal

    Laboratory for Infection and Immune Biology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne; Cologne, 50931, Germany

    2 shared publications
  • Florian Klein

    Laboratory of Experimental Immunology, Institute of Virology, Faculty of Medicine and University Hospital Cologne, University of Cologne

    2 shared publications
  • Katja Hoffmann

    Institute of Virology, University Medical Center, Faculty of Medicine, University of Freiburg; Freiburg, 79104, Germany

    2 shared publications
  • Ajit R. Ramamohan

    Department of Molecular Biosciences, The University of Texas at Austin; Austin, TX, 78712, USA

    1 shared publication
  • Ann-Kathrin Kohl

    Institute of Virology, University Medical Center, Faculty of Medicine, University of Freiburg; Freiburg, 79104, Germany

    1 shared publication

Latest Publications

  • Open Access

    B cell response to HCMV gH/UL116 elicits neutralizing and FcγR-activating antibodies

    by Artem Ashurov, Katja Hoffmann, Ajit R. Ramamohan, Krithika P. Karthigeyan, Anna Ashurov, Markus Rotzler, Ann-Kathrin Kohl, Gretel M. Torres, Christian Binuya, Caitlin Williams, et al.

    SUMMARY: Humoral immune mechanisms that can contribute to limiting HCMV disease include neutralizing antibodies that block viral entry and Fc-mediated effector functions that promote elimination of infected cells. Here, we identify the gH/UL116 envelope complex as a naturally immunogenic target that elicits antibodies capable of mediating both of these immune mechanisms. Using single-cell sorting of antigen-specific memory B cells, we isolated gH/UL116-reactive monoclonal antibodies from HCMV-seropositive donors. Epitope mapping showed that gH binding was required for virus neutralization, whereas UL116 targeting was associated with potent and broad Fcγ receptor (FcγR) activation. Furthermore, cryo-electron microscopy provided high-resolution structures revealing how UL116-specific antibodies bind gH/UL116. In mice, gH/UL116 immunization elicited serum IgG responses whose binding titers strongly correlated with both neutralization and mouse FcγR activation. Together, these findings provide an epitope-level map linking antibody specificity to neutralization and FcγR activation across HCMV gH-associated complexes and position gH/UL116 as a promising HCMV vaccine candidate.

  • Open Access

    Structural characterization of antibodies for synergistic HCMV neutralization

    by Artem Ashurov, Jory A. Goldsmith, Anna Ashurov, Zeyi Yu, Manuel Koch, Nica Classen, Linda Schlachter, Zahra Saidi, Danylo Shestopal, Katja Hoffmann, et al.

    The limited mechanistic understanding of Human Cytomegalovirus (HCMV) infection and neutralization has hindered the effective application of antibodies for HCMV prevention and therapy. To address this, we conducted high-resolution cryo-EM analysis of 17 human monoclonal antibodies targeting HCMV glycoproteins gH and gL. This analysis revealed a landscape of vulnerable epitopes, including detailed binding modes, spatial orientations, and structural features associated with distinct neutralization phenotypes. By comprehensively characterizing the neutralizing properties of these antibodies and their combinations, we identified synergistic antibody cocktails that enhance the neutralization capacity of individual antibodies. Notably, while single antibodies only partially neutralized HCMV, their synergistic combinations achieved substantially more complete inhibition. Together, these findings delineate structural correlates of HCMV neutralization and establish functional principles for antibody-based combinatorial targeting of HCMV.